5:35 PM
 | 
Oct 30, 2012
 |  BC Extra  |  Clinical News

Neuraltus reports Phase II data for NP001 in ALS

Neuraltus Pharmaceuticals Inc. (Palo Alto, Calif.) plans to start Phase III testing of NP001 to treat amyotrophic lateral sclerosis (ALS) in 2H13 despite reporting top-line data from a Phase II trial showing that NP001 missed the primary and secondary endpoints vs. placebo. Neuraltus said high-dose NP001 non-significantly slowed the...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >